Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Venous thromboembolism (VTE) is one of the serious complications after robot-assisted radical cystectomy (RARC). This study aims to investigate the optimal duration of VTE prophylaxis and the predictive value of D-dimer measurement on the early detection of VTE. METHODS: Retrospectively, we evaluated 86 RARC patients from July 2020 to September 2023. Thromboprophylaxis was modified two times (July 2020-; no-enoxaparin administration, June 2021-; enoxaparin for one week postoperatively, December 2022-; for two weeks), and patients were divided into three groups according to the duration. For early detection of VTE, D-dimer was measured postoperatively over time. In cases of D-dimer exceeding 10 μg/mL, contrast-enhanced CT was performed. The incidence of VTE was analyzed, and multivariate analysis was performed to identify the predictive factors. RESULTS: Of the 40 patients who experienced postoperative D-dimer levels > 10 μg/mL, 37 underwent CT or ultrasound. VTE was observed in 10/26 cases (38%) in the no-enoxaparin group, 8/36 cases (22%) in the one-week group, and 1/24 cases (4%) in the two-week group, with a significant difference in incidence between the no-enoxaparin and 2-week groups (p = 0.005). Symptomatic VTE was observed in only one case in the no-enoxaparin group. Multivariate analyses of VTE predictive factors showed significant differences in D-dimer levels ≥ 12 on postoperative day 1 (OR = 14.2, 95% CI 2.47-81.1, p = 0.003) and enoxaparin administration for two weeks (OR = 0.10, 95% CI 0.01-0.96, p = 0.046). CONCLUSION: Chemoprophylaxis for 2 weeks significantly reduces the risk of VTE after RARC. In addition, routine measurement of D-dimer enables early detection of asymptomatic VTE, helping to prevent the development of symptomatic VTE.

DOI： 10.1111/iju.70066

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND/AIM: This study investigated the correlation between body mass index (BMI, kg/m2) and clinical outcomes in patients with advanced renal cell carcinoma (RCC) treated with ipilimumab and nivolumab. PATIENTS AND METHODS: A total of 113 patients with advanced RCC, treated with first-line ipilimumab and nivolumab were analyzed. Patients were divided into two groups based on their BMI at treatment initiation: the high BMI (BMI ≥25) and the low BMI group (BMI <25). The objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and duration of response (DOR) were analyzed to compare the two groups. RESULTS: Patient characteristics for the high BMI (n=30) and the low BMI (n=83) were as follows: median age at treatment initiation (70 years for both groups), percentage of male patients (77% vs. 82%), International Metastatic RCC Database Consortium (IMDC) poor-risk category (23% vs. 33%), the presence of liver metastasis (7% vs. 8%). The ORR was 53% (16/30) in the high BMI and 37% (29/77) in the low BMI (p=0.01). The median OS was not estimated in the high BMI and 33 months in the low BMI (p=0.049). Multivariable analysis identified IMDC poor-risk status with a hazard ratio (HR) of 2.31 and the presence of liver metastasis with an HR of 4.83 as independent factors affecting OS. CONCLUSION: A higher ORR for the combination of ipilimumab and nivolumab was observed in patients with high BMI compared to those with low BMI. IMDC poor risk and the presence of liver metastasis significantly influenced the prognosis of patients with advanced RCC treated with the combination.

DOI： 10.21873/anticanres.17635

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Background: Urinary tract infection (UTI) is predominantly caused by uropathogenic Escherichia coli (UPEC). Previous studies have reported that the fimbriae of UPEC are involved in virulence and antimicrobial resistance. We aimed to analyze the fimbrial gene profiles of UPEC and investigate the specificity of these expressions in symptomatic UTI, urinary device use, and levofloxacin (LVFX) resistance/extended-spectrum beta-lactamase (ESBL) production. Methods: A total of 120 UPEC strains were isolated by urine culture between 2019 and 2023 at our institution. They were subjected to an antimicrobial susceptibility test and polymerase chain reaction (PCR) to identify 14 fimbrial genes and their association with clinical outcomes or antimicrobial resistance. Results: The prevalence of the papG2 gene was significantly higher in the symptomatic UTI group by multivariate analyses (OR 5.850, 95% CI 1.390-24.70, p = 0.016). The prevalence of the c2395 gene tended to be lower in the symptomatic UTI group with urinary devices (all p < 0.05). In LVFX-resistant UPEC strains from both the asymptomatic bacteriuria (ABU) and the symptomatic UTI group, the expression of the papEF, papG3, c2395, and yadN genes tended to be lower (all p < 0.05). Conclusion: The fimbrial genes of UPEC are associated with virulence and LVFX resistance, suggesting that even UPEC with fewer motility factors may be more likely to ascend the urinary tract in the presence of the urinary devices. These findings may enhance not only the understanding of the virulence of UPEC but also the management of UTI.

DOI： 10.3390/antibiotics14050468

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

With the advancement of modern ureteroscopes and laser technology, kidney-sparing surgery(KSS)has an expanding role for patients with upper tract urothelial carcinoma(UTUC), although radical nephroureterectomy remains the gold standard. Patients with UTUC are generally elderly and often have major medical comorbidities. As such, KSS is recommended for patients with imperative indications, such as bilateral disease, renal insufficiency, or a solitary kidney, while maintaining renal function, resulting in the avoidance of potential long-term cardiovascular morbidity and hemodialysis. In addition, KSS is also advocated for low-risk patients(elective indication)based on the risk stratifications recommended by each guideline. The big issue of risk stratifications is their narrow indications at the cost of providing accuracy, but the current elective indications have been updated and expanded year by year. KSS includes endoscopic management through antegrade or retrograde access to the upper tract and segmental ureterectomy. Thulium: YAG laser in combination with Ho: YAG laser is recently used for KSS due to the advantages of its shallow penetration depth in tissue, with a reduced risk of upper urinary tract perforation. The concern regarding KSS is a high recurrence rate. Adjuvant intracavitary instillation to the upper tract has the potential to reduce the risk of recurrence. The phase Ⅲ trial assessing a mitomycin-containing reverse thermal gel (JelmytoTM)revealed the promising result despite their use not being approved in Japan. Therefore, KSS is assumed to have an increasing demand for patients with UTUC in our aged society and is expected to be widely utilized nationwide.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

For small renal tumors, nephron-preserving treatment, including partial nephrectomy or ablation therapy, is recommended. According to major guidelines, ablation therapies are advised for patients who are deemed not suitable to undergo surgery due to an advanced age or the presence of comorbidities. However, compared with surgery, ablation therapy can result in superior safety and functional outcomes. The present review discusses the factors affecting decision-making as regards treatment options for small renal tumors. When determining an appropriate treatment option, tumor locations, as well as the condition and preferences of the patient, are considered. Scoring systems, such as the RENAL Nephrometry Score can assist in guiding treatment decisions. However, surgery may be the preferred approach for tumors near major vessels and collecting systems. For endophytic tumors, partial nephrectomy can be challenging due to the difficulty in visualizing intra-parenchymal tumors during the procedure, whereas ablation therapies may be inferior to partial nephrectomy. Although treatment selection for small renal tumors can be affected by tumor location, partial nephrectomy remains the gold standard for numerous cases.

DOI： 10.3892/mi.2025.247

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: To examine whether antimicrobial prophylaxis based on screening rectal cultures using selective media prevented acute bacterial prostatitis following transrectal prostate biopsy (TRPB). METHODS: In this multicenter, randomized controlled trial, we enrolled 403 patients undergoing TRPB with low risks of infectious complications. Patients were randomized into a cultured group (CG) or no cultured group (NCG). In the CG, patients with positive culture results for fluoroquinolone (FQ)-resistant or extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) used piperacillin/tazobactam as prophylaxis, and those with negative culture results and in the NCG used levofloxacin. The primary endpoint was the incidence of acute prostatitis after TRPB. The secondary endpoint was the accuracy of the selective media. RESULTS: Of 373 patients (CG, 187; NCG, 186), 67 were positive, and 120 were negative for rectal culture in the CG. The overall incidence of prostatitis after TRPB was 1.1% (n=4). The incidences in the CG and the NCG were 1.6% (n=3, all negative-culture cases) and 0.5% (n=1), respectively, without significant difference (P=0.3). No prostatitis occurred in the positive-culture group. The sensitivity and specificity of the levofloxacin-insusceptible selective media were 98.1% and 94.7%, respectively. CONCLUSION: Screening with selective media before TRPB in patients with low infectious risks may provide additive value to preventing post-biopsy prostatitis. Piperacillin/tazobactam can be considered when FQ-resistant or ESBL-producing E. coli is detected.

DOI： 10.1016/j.urology.2024.12.018

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVES: This study aimed to compare the clinical outcomes of robot-assisted partial nephrectomy (RAPN) and image-guided percutaneous cryoablation (IG-PCA) for clinical T1 renal cell carcinoma. MATERIALS AND METHODS: We conducted a retrospective analysis of 679 patients with clinical T1 renal cell carcinoma treated with RAPN or IG-PCA between 2012 and 2021. Propensity scores were calculated via logistic analysis to adjust for imbalances in baseline characteristics. We compared oncological and functional outcomes between the 2 treatment groups. RESULTS: Following the matching process, 108 patients were included in each group. No patient in the RAPN group developed local recurrence. In the IG-PCA group, three patients experienced local tumor progression. The patients underwent salvage thermal ablations by the secondary technique; 2 underwent IG-PCA and 1 underwent microwave ablation, resulting in a local control rate of 100%. The Kaplan-Meier analysis showed no statistically significant differences between the groups in terms of 5-year recurrence-free survival, metastasis-free survival, and overall survival (log-rank test; P = 0.11, P = 0.64, and P = 0.17, respectively). No significant differences were observed in the 2 treatments in major and overall complication rates (P = 0.75 and P = 0.82, respectively). Both groups showed similar rates of less than 10% estimated glomerular filtration rate decline at 12 months post-treatment and 5-year renal function preservation rates (P = 0.88 and P = 0.38, respectively). CONCLUSIONS: IG-PCA demonstrated oncological outcomes comparable to those of RAPN. RAPN addressed the disadvantages of conventional procedures and allowed for safety outcomes comparable to IG-PCA.

DOI： 10.1016/j.urolonc.2024.09.012

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVES: The advancement of laparoscopic surgery has allowed surgeons to see finer anatomical structures during surgery. As a result, several issues have arisen regarding Gerota fascia that cannot be explained by previous interpretations, such as its various forms observed during surgery. To address these issues, we histologically examined the structure of Gerota fascia. METHODS: Specimens for study were prepared from kidneys with Gerota fascia from four cadavers, and the structure was studied histologically. Its thickness and collagen fiber area ratios were measured using ImageJ and compared to those of the epimysium of the rectus abdominis muscle. RESULTS: Connective tissue that appeared to be Gerota fascia was observed in 26 specimens. Histologically, the basic structure of Gerota fascia was a sandwich-like structure with a thin layer of thick, long collagen fibers in the central layer, and small granular collagen fibers scattered at the edges. However, not all areas observed had a similar structure; eight specimens were composed only of small granular collagen fibers. The average thickness of the Gerota fascia was 466 μm, and the area ratio of collagen was 27.1%. In contrast, the epimysium was much thicker than Gerota fascia, and its collagen fibers were much thicker and denser. CONCLUSIONS: Gerota fascia, unlike the epimysium, was a very thin and fragile layer of collagen fibers, and its structure was diverse. This explains why Gerota fascia was observed in various states during surgery. It is important for surgeons to understand the properties of Gerota fascia and to treat it appropriately.

DOI： 10.1111/iju.15596

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本性科学会  

researchmap

Language：Japanese   Publisher：(一社)日本性機能学会  

researchmap

Language：Japanese   Publisher：(一社)日本性機能学会  

researchmap

Language：Japanese   Publisher：(一社)日本性機能学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Authorship：Lead author   Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Hindawi Limited  

Objectives. It is still not clear how the intravesical instillation of drugs affects rat urinary frequency. This study aimed to examine the dynamics of intravesical treatments’ treatment effect on rat urinary frequency models by real-time and extended monitoring using a novel continuous urination monitoring system. Methods. Nine eleven-week-old female Wistar rats were divided into three groups to receive intravesical instillation of 0.1% acetic acid (AA), 1.0% AA, or phosphate-buffered saline (PBS). Thirty minutes later, these drugs were voided, and rats were moved to a continuous urination monitoring system, UM-100. UM-100 monitored rat urination quantitatively and continuously for 24 hours. Rats were then euthanized, and histopathologic examinations using a damage score validated the severity of bladder inflammation. We used nine additional rats to determine the treatment effect of various drugs against the urinary frequency. These rats were also treated with 1.0% AA in the same way and divided into three groups (n = 3 each) to receive intravesical instillation of lidocaine, silver nitrate (AgNO₃), or dimethyl sulfoxide (DMSO), respectively. Thirty minutes later, rats were catheterized again and moved to the UM-100, and their voiding was monitored for 24 hours. Results. Intravesical instillation of AA increased the urinary frequency and decreased the mean voided volume (VV) in a concentration-dependent manner, with statistical significance at a concentration of 1.0% (urinary frequency; , mean VV; , respectively) compared with PBS. Histopathological analysis of these models demonstrated a significantly higher damage score of bladder mucosa in both 0.1% AA and 1.0% AA compared with PBS, with the severity in concordance with the clinical severity of urinary frequency (0.1% AA: , 1.0% AA: ). Moreover, intravesical instillation of lidocaine, AgNO₃, and DMSO decreased the urinary frequency. Continuous monitoring with UM-100 also demonstrated that the treatment effect of these intravesically instilled drugs occurred only at night. Conclusions. The extended monitoring of rat urination by UM-100 revealed a significant fluctuation in the treatment effect of intravesically instilled drugs between day and night. These findings may help establish novel therapies for urinary frequency.

DOI： 10.1155/2024/6505595

researchmap

Other Link： http://downloads.hindawi.com/journals/vmi/2024/6505595.xml

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

Abstract

Background

Transgender individuals undergo the gender‐affirming hormone therapy (GAHT) to achieve physical changes consistent with their gender identity. Few studies are available on the long‐term safety and efficacy of GAHT.

Objectives

To investigate the long‐term physical effects and the safety of the testosterone therapy for trans men and to assess the impact of differential hormone dose.

Materials and methods

Trans men who initiated GAHT between May 2000 and December 2021 were included in this retrospective analysis. Physical findings (body mass index, body fat percentage (BFP), lean body mass (LBM), and grip strength), blood testing results (hemoglobin, hematocrit, uric acid, creatinine, total cholesterol, triglycerides, and total testosterone), and menstrual cessation were recorded. We assessed the effects of testosterone on body composition changes and laboratory parameters, comparing a low‐dose group (≤ 62.5 mg/wk) to a high‐dose group (&gt; 62.5 mg/wk).

Results

Of 291 participants, 188 patients (64.6%) were in the low‐dose group and 103 (35.4%) in the high‐dose group. Cumulative menstrual cessation rates up to 12 months were not significantly different between groups. Both groups showed a decrease in BFP and an increase in LBM during the first year of therapy, followed by a slight increase in both over the long term. The high‐dose group exhibited greater LBM gains during the first year. Higher hormone doses and lower initial LBM values were associated with LBM increases at 3 and 6 months (3 mo, P = 0.006, P &lt; 0.001; 6 mo, P = 0.015, P &lt; 0.001). There were no long‐term, dose‐dependent side effects such as polycythemia or dyslipidemia.

Conclusion

Long‐term GAHT for trans men is safe and effective. Low‐dose testosterone administration is sufficient to increase LBM in trans men. Higher testosterone doses can lead to an earlier increase in muscle mass.

DOI： 10.1111/andr.13640

researchmap

Authorship：Lead author   Language：Japanese   Publisher：(一社)日本生殖医学会  

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

DOI： 10.1016/j.clgc.2024.102097

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Radiological tumor burden has been reported to be prognostic in many malignancies in the immunotherapy era, yet whether it is prognostic in patients with metastatic urothelial carcinoma (mUC) treated with pembrolizumab remains uninvestigated. We sought to assess the predictive and prognostic value of radiological tumor burden in patients with mUC. METHODS: We performed a retrospective analysis of 308 patients with mUC treated with pembrolizumab. Radiological tumor burden was represented by baseline tumor size (BTS) and baseline tumor number (BTN). Optimal cut-off value of BTS was determined as 50 mm using the Youden index (small BTS: n = 194, large BTS: n = 114). Overall (OS), cancer-specific (CSS), progression-free survival (PFS), and objective response rate (ORR) were compared. Non-linear associations between BTS and OS and CSS were evaluated using restricted cubic splines. RESULTS: Patients with large BTS were less likely to have undergone the surgical resection of the primary tumor (P = 0.01), and more likely to have liver metastasis (P < 0.001) and more metastatic lesions (P < 0.001). On multivariable analyses controlling for the effects of confounders (resection of primary tumor, metastatic site, number of metastases and lactate dehydrogenase level), large BTS and high BTN were independently associated with worse OS (HR 1.52; P = 0.015, and HR 1.69; P = 0.018, respectively) and CSS (HR 1.59; P = 0.01, and HR 1.66; P = 0.031, respectively), but not PFS. Restricted cubic splines revealed BTS was correlated with OS and CSS in linear relationships. Additionally, large BTS was significantly predictive of lower ORR and complete response rate on univariable analyses (P = 0.041 and P = 0.032, respectively), but its association disappeared on multivariable analyses. CONCLUSION: Radiological tumor burden has independent prognostic value with a linear relationship in pembrolizumab-treated patients with mUC and might help drive the earlier introduction of second-line pembrolizumab and/or switching to subsequent therapies.

DOI： 10.1016/j.urolonc.2023.11.009

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

This review presents the latest insights on robot-assisted kidney autotransplantation (RAKAT). RAKAT is a minimally invasive surgical procedure and represents a promising alternative to conventional laparoscopic nephrectomy followed by open kidney transplantation for the treatment of various complex urological and vascular conditions. RAKAT can be performed either extracorporeally or intracorporeally. Additionally, a single-port approach can be performed through one small incision without the need to reposition the patient. Of 86 patients undergoing RAKAT, 8 (9.3%) developed postoperative > Grade 2 Clavien-Dindo (CD) complications. Although the feasibility of RAKAT was established in 2014, the long-term efficacy and safety along with outcomes of this surgical approach are still being evaluated, and additional studies are needed. With improvements in the technology of RAKAT and as surgeons gain more experience, RAKAT should become increasingly used and further refined, thereby leading to improved surgical outcomes and improved patients' quality of life.

DOI： 10.1111/iju.15426

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本臨床腎移植学会  

researchmap

Language：Japanese   Publisher：(一社)日本臨床腎移植学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(NPO)日本血管外科学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

One-third of renal cell carcinomas (RCCs) without metastases develop metastatic disease after extirpative surgery for the primary tumors. The majority of metastatic RCC cases, along with treated primary lesions, involve limited lesions termed "oligo-recurrent" disease. The role of metastasis-directed therapy (MDT), including stereotactic body radiation therapy (SBRT) and metastasectomy, in the treatment of oligo-recurrent RCC has evolved. Although the surgical resection of all lesions alone can have a curative intent, SBRT is a valuable treatment option, especially for patients concurrently receiving systemic therapy. Contemporary immune checkpoint inhibitor (ICI) combination therapies remain central to the management of metastatic RCC. However, one objective of MDT is to delay the initiation of systemic therapies, thereby sparing patients from potentially unnecessary burdens. Undertaking MDT for cases showing progression under systemic therapies, known as "oligo-progression", can be complex in considering the treatment approach. Its efficacy may be diminished compared to patients with stable disease. SBRT combined with ICI can be a promising treatment for these cases because radiation therapy has been shown to affect the tumor microenvironment and areas beyond the irradiated sites. This may enhance the efficacy of ICIs, although their efficacy has only been demonstrated in clinical trials.

DOI： 10.3390/cancers15245873

PubMed

researchmap

Authorship：Lead author   Language：Japanese   Publisher：GID(性同一性障害)学会  

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese   Publisher：(一社)日本排尿機能学会  

researchmap

Language：Japanese   Publisher：(一社)日本排尿機能学会  

researchmap

Language：Japanese   Publisher：(一社)日本排尿機能学会  

researchmap

Language：Japanese   Publisher：(一社)日本排尿機能学会  

researchmap

Language：Japanese   Publisher：日本女性骨盤底医学会  

researchmap

Language：Japanese   Publisher：日本女性骨盤底医学会  

researchmap

Authorship：Lead author   Language：Japanese   Publisher：(一社)日本性機能学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：GID(性同一性障害)学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Wiley  

Introduction

Tape infection after insertion of tension‐free vaginal tape is a well‐known but rare complication. We report a patient who experienced a subcutaneous abscess 19 years after the surgery.

Case presentation

A 41‐year‐old woman presented with fever and lower abdominal pain. She had undergone tension‐free vaginal tape insertion for stress urinary incontinence 19 years prior. She had asymptomatic dysuria. After an abscess incision and 1‐week treatment with antibiotics, she underwent surgery to remove the tape and the abscess without complications.

Conclusion

Tension‐free Vaginal Tape insertion could be a potential risk of asymptomatic dysuria, resulting in urinary tract infection. In this case, removal of tape was necessary for controlling subcutaneous abscess resulting from the presence of tension‐free vaginal tape.

DOI： 10.1002/iju5.12440

researchmap

Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/iju5.12440

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.

DOI： 10.18926/AMO/62820

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Authorship：Corresponding author   Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Wiley  

Abstract

We report a patient with adrenal incidentaloma due to synchronous and isolated metastasis from lung cancer, which is a relatively rare condition. Close checkups for incidentaloma in oncologic patients are mandatory, leading to successful operation.

DOI： 10.1002/ccr3.3996

researchmap

Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ccr3.3996

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：腎移植・血管外科研究会  

researchmap

Language：Japanese   Publisher：腎移植・血管外科研究会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：The West Japan Urological Association  

Scopus

researchmap

Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Japanese Urological Association  

DOI： 10.5980/jpnjurol.107.239

Scopus

PubMed

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(有)科学評論社  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：岡山赤十字病院医学雑誌編集委員会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡学会  

researchmap

Language：Japanese   Publisher：岡山赤十字病院医学雑誌編集委員会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：岡山赤十字病院医学雑誌編集委員会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(一社)日本抗加齢医学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：日本赤十字社医学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：日本泌尿器内視鏡学会  

DOI： 10.11302/jsejje.27.395

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

researchmap